Physician profile
Peter G Bernad
NPI 1336110477
$18,963.90
in general payments reported to CMS, 2019-2025
65 companies · $2,608 in 2025
The $2,608 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $1,360 · 2021: $2,277 · 2022: $2,884 · 2023: $2,927 · 2024: $5,392 · 2025: $2,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,328 · Consulting Fee: $2,205 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,327.94 |
| Consulting Fee | $2,205.00 |
| Education | $394.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,791.06 | 2020-2025 | Skyclarys, Vumerity, Tysabri |
| Abbvie INC. | $1,341.39 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,329.59 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,126.80 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Harmony Biosciences LLC | $884.90 | 2020-2025 | Wakix |
| Ucb, INC. | $876.19 | 2019-2024 | Briviact, Nayzilam |
| Lilly USA, LLC | $850.01 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Amneal Pharmaceuticals LLC | $783.98 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Pfizer INC. | $696.59 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $665.72 | 2019-2025 | Hetlioz, Ponvory, Fanapt |
| Argenx US, INC. | $479.82 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sunovion Pharmaceuticals INC. | $433.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $392.04 | 2022-2025 | Nuedexta, Rexulti |
| Neurocrine Biosciences, INC. | $379.04 | 2020-2025 | Ingrezza, Ongentys |
| Avanir Pharmaceuticals, INC. | $365.70 | 2021-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bernad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.